Clinical Trials Logo

Scorpion Stings clinical trials

View clinical trials related to Scorpion Stings.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05125796 Completed - Scorpion Stings Clinical Trials

Analgesic Use for Pain Relief in Scorpion Sting

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

In scorpion stings, patients mostly apply with the complaint of pain. Emergency physicians need to relieve this pain quickly.

NCT ID: NCT03943199 Completed - Pain Clinical Trials

Comparison of Lysine Clonixinate, Ketorolac and Metamizole Sodium in Scorpion Stings

Start date: May 5, 2019
Phase: N/A
Study type: Interventional

The cases of scorpion stings are matters of medical importance, where Mexico is considered as one of the main countries of such public health problem.

NCT ID: NCT03622125 Completed - Scorpion Stings Clinical Trials

Decrease in Temperature as a Pagtonomic Sign by Scorpion Sting

Start date: May 20, 2017
Phase:
Study type: Observational

The scorpion sting is a medical disease, for the signs and symptoms presented; Sometimes patients do not know the animal that causes these symptoms; the bibliography marks the decrease in temperature as a sign to be presented.

NCT ID: NCT01599936 Completed - Clinical trials for Scorpion Sting Envenomation

Open Label Clinical Trial of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation

Start date: April 2004
Phase: Phase 3
Study type: Interventional

There is no FDA approved therapy for the treatment of scorpion envenomation. Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening. Patients stung by Centruroides scorpions develop a clinical syndrome which may require sedation with benzodiazepines and observation for 6 to 28 hours of intensive care monitoring. A safe therapy is necessary to halt the progression of symptoms early in the clinical course while avoiding the clinical deterioration that can occur en route to a tertiary facility. Alacramyn® is anticipated to be safer and more effective than the present standard of care, midazolam, and faster-acting thus eliminating the need to transport most rural patients and reducing hospitalization time.

NCT ID: NCT01599923 Completed - Clinical trials for Scorpion Sting Envenomation

Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation

Start date: May 2005
Phase: Phase 3
Study type: Interventional

There is no FDA approved therapy for the treatment of scorpion envenomation in the United States. Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening. Patients stung by Centruroides scorpions develop a clinical syndrome which may require sedation with benzodiazepines and observation for 6 to 28 hours of intensive care monitoring. A safe therapy is necessary to halt the progression of symptoms early in the clinical course while avoiding the clinical deterioration that can occur en route to a tertiary facility. Alacramyn® is anticipated to be safer and more effective than the present standard of care in the United States, midazolam, and faster-acting thus eliminating the need to transport most rural patients and reducing hospitalization time.

NCT ID: NCT01415830 Completed - Scorpion Sting Clinical Trials

Compare Two Anti-Scorpion Venom Serum In Children

Start date: August 2011
Phase: Phase 3
Study type: Interventional

The morbidity associated with scorpion sting intoxication presents an endemic pattern in the country, where there are highly venomous species of scorpions so the scorpion sting intoxication (IPPA) is considered a medical emergency. On the other hand, there is scarce scientific literature from different controlled studies evaluating anti-scorpion serum, considering clinical severity scales, lab results and their safety. The aim of this study is to compare the efficacy and safety of scorpion sting treatment, using two sera, one produced by Birmex versus Alacramyn ® (Bioclon).

NCT ID: NCT01336660 Completed - Clinical trials for Poisoning by Scorpion Sting

A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in Morocco

Start date: July 21, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This study has the objective to demonstrate the effectiveness of Alacramyn NAMO in the treatment of North Africa and Middle East scorpions envenomation by reducing the severity of envenomation. The primary endpoint is make a comparison between antivenom and placebo groups, at 4 hours after study drug, of the number of cases showing improvement in class of envenomation.

NCT ID: NCT00739440 Completed - Scorpion Sting Clinical Trials

Randomized Controlled Trial to Compare Two Anti-scorpion Serums

Start date: August 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficiency and safety of the treatment against sting scorpion, using two serums, one elaborated by Birmex versus other commercial serum

NCT ID: NCT00696683 Completed - Clinical trials for Scorpion Sting Envenomation

Establishment of Natural History of Scorpion Envenomation

Start date: August 2004
Phase: N/A
Study type: Observational

This retrospective study was conducted to collect data from approximately 100 patients from 6 months to 18 years of age who were stung by a scorpion but were not treated with antivenom. The study consisted of a review of hospital records of patients who were admitted for intensive care management of scorpion envenomation, at the only two hospitals in North America known to admit children routinely for scorpion sting management without antivenom. The standard of care consisted of symptomatic and supportive care, including airway maintenance, fluid and electrolyte support and, if necessary, sedation.

NCT ID: NCT00685230 Completed - Clinical trials for Scorpion Sting Envenomation

Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients

Start date: May 2004
Phase: Phase 2/Phase 3
Study type: Interventional

There is no FDA approved therapy for the treatment of scorpion envenomation, Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening. Patients stung by Centruroides scorpions develop a clinical syndrome which may require sedation with benzodiazepines and observation for 6 to 28 hours of intensive care monitoring. A safe therapy is necessary to halt the progression of symptoms early in the clinical course while avoiding the clinical deterioration that can occur en route to a tertiary facility. Alacramyn® is anticipated to be safer and more effective than the present standard of care, midazolam, and faster-acting such that the need for transport of most rural patients will be eliminated and will reduce hospitalization time. The working hypotheses are as follows: 1. The investigational antivenom is safe as treatment of scorpion sting envenomation. 2. The investigational antivenom is effective as treatment of scorpion sting envenomation.